Catabasis Pharmaceuticals, Inc.
-
Ticker
CATB
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 11-50 Employees
- Based in Boston, Massachusetts
At Catabasis Pharmaceuticals, their mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy.
Catabasis Pharmaceuticals, Inc.
Most Recent Annual Report
MOST RECENT
2020 Annual Report and Form 10K
Older/Archived Annual Reports